Researchers have found that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against the deadly virus in healthy adults.The findings by APPROACH, an early-stage clinical trial are based on "mosaic" technology that combines immune-stimulating proteins from four different HIV strains, representing different types of virus from around the globe.
The new vaccine:
- The new vaccine regimen called as "Ad26 mosaic".
- It was well-tolerable.
- In addition,capable of generating anti-HIV immune responses in healthy HIV-negative adults.
- Importantly, Ad26 mosaic is most protective in pre-clinical studies in animals.
- Furthermore, elicited among the greatest immune responses in the study participants.
- Anthony S. Fauci, Director at the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland.
- He said,a safe and effective HIV vaccine would be a powerful tool to reduce new HIV infections worldwide.
- In addition,help bring about a durable end to the HIV/AIDS pandemic.
- By exploring multiple promising avenues of vaccine development research.
- We expand our opportunities to achieve these goals," Fauci added.
- The results were presented at the ninth International AIDS Society Conference on HIV Science in Paris.
- For the study, APPROACH involved nearly 400 volunteers in the US, Rwanda.
- In addition,Uganda, South Africa and Thailand who were randomly assign.
- To receive one of seven experimental vaccine regimens.
Ad26 mosaic vaccine:
- The Ad26 mosaic vaccine delivers its four immunogens to human cells.
- In addition,through a common cold virus that is genetically engineer to cause infection but not illness.
- The results showed that Ad26 is safe.
- Also,triggered a strong immune response to the different HIV strains in the volunteers.
- In addition,the promising, early-stage results from the APPROACH study.
- Furthermore,supports evaluation of these candidate vaccines to assess their ability to protect.
- In addition, those at risk of acquiring HIV, the researchers said.